# The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV)

> **NCT07101536** · NA · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 40 (estimated)

## Conditions studied

- EBV-associated Tumors

## Interventions

- **BIOLOGICAL:** EBV mRNA vaccine
- **BIOLOGICAL:** Immune Checkpoint Inhibitors, ICIs

## Key facts

- **NCT ID:** NCT07101536
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101536, "The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07101536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*